Your browser doesn't support javascript.
loading
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.
Paller, Amy S; Siegfried, Elaine C; Thaçi, Diamant; Wollenberg, Andreas; Cork, Michael J; Arkwright, Peter D; Gooderham, Melinda; Beck, Lisa A; Boguniewicz, Mark; Sher, Lawrence; Weisman, Jamie; O'Malley, John T; Patel, Naimish; Hardin, Megan; Graham, Neil M H; Ruddy, Marcella; Sun, Xian; Davis, John D; Kamal, Mohamed A; Khokhar, Faisal A; Weinreich, David M; Yancopoulos, George D; Beazley, Bethany; Bansal, Ashish; Shumel, Brad.
  • Paller AS; Northwestern University Feinberg School of Medicine, Chicago, Illinois; Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois.
  • Siegfried EC; Saint Louis University, St. Louis, Missouri; Cardinal Glennon Children's Hospital, St. Louis, Missouri.
  • Thaçi D; Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany.
  • Wollenberg A; Ludwig-Maximilian University, Munich, Germany.
  • Cork MJ; University of Sheffield, Sheffield, United Kingdom.
  • Arkwright PD; Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, United Kingdom.
  • Gooderham M; Probity Medical Research, Peterborough, Ontario, Canada; SKiN Centre for Dermatology, Peterborough, Ontario, Canada; Queen's University, Kingston, Ontario, Canada.
  • Beck LA; University of Rochester Medical Center, Rochester, New York.
  • Boguniewicz M; National Jewish Health, Denver, Colorado; University of Colorado School of Medicine, Denver, Colorado.
  • Sher L; Peninsula Research Associates, Rolling Hills Estates.
  • Weisman J; Advanced Medical Research, PC, Atlanta, California.
  • O'Malley JT; Sanofi, Cambridge, Massachusetts.
  • Patel N; Sanofi, Cambridge, Massachusetts.
  • Hardin M; Sanofi, Cambridge, Massachusetts.
  • Graham NMH; Regeneron Pharmaceuticals, Inc, Tarrytown New York.
  • Ruddy M; Regeneron Pharmaceuticals, Inc, Tarrytown New York.
  • Sun X; Regeneron Pharmaceuticals, Inc, Tarrytown New York.
  • Davis JD; Regeneron Pharmaceuticals, Inc, Tarrytown New York.
  • Kamal MA; Regeneron Pharmaceuticals, Inc, Tarrytown New York.
  • Khokhar FA; Regeneron Pharmaceuticals, Inc, Tarrytown New York.
  • Weinreich DM; Regeneron Pharmaceuticals, Inc, Tarrytown New York.
  • Yancopoulos GD; Regeneron Pharmaceuticals, Inc, Tarrytown New York.
  • Beazley B; Regeneron Pharmaceuticals, Inc, Tarrytown New York.
  • Bansal A; Regeneron Pharmaceuticals, Inc, Tarrytown New York.
  • Shumel B; Regeneron Pharmaceuticals, Inc, Tarrytown New York. Electronic address: Brad.shumel@regeneron.com.
J Am Acad Dermatol ; 83(5): 1282-1293, 2020 Nov.
Article en En | MEDLINE | ID: mdl-32574587
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Corticoesteroides / Dermatitis Atópica / Anticuerpos Monoclonales Humanizados Tipo de estudio: Clinical_trials / Observational_studies Límite: Child / Female / Humans / Male Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Corticoesteroides / Dermatitis Atópica / Anticuerpos Monoclonales Humanizados Tipo de estudio: Clinical_trials / Observational_studies Límite: Child / Female / Humans / Male Idioma: En Año: 2020 Tipo del documento: Article